Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Ther ; 16(8): 1490-9, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18560421

RESUMO

Patients with mutations in the Artemis gene display a complete absence of T- and B lymphocytes, together with increased cellular radiosensitivity; this leads to a radiosensitive severe combined immunodeficiency (RS-SCID). Allogenic hematopoietic stem-cell (HSC) transplantation is only partially successful in the absence of an human leukocyte antigen-genoidentical donor, and this has prompted a search for alternative therapeutic approaches such as gene therapy. In this study, a self-inactivated lentiviral vector expressing Artemis was used to complement the Artemis knockout mouse (Art(-/-)). Transplantation of Artemis-transduced HSCs into irradiated Art(-/-) mice restored a stable (over a 15-month period of follow-up) and functional T- and cell repertoire that was comparable to that of control mice. The success of secondary transplantations demonstrated that the HSCs had been transduced. One of thirteen mice developed a thymoma 6 months after gene therapy. Although thymic cells were seen to be carrying two lentiviral integration sites, there was no evidence of lentivirus-driven oncogene activation. The Art(-/-) mice were found to be prone to develop T-cell lymphomas, either spontaneously or after irradiation. These data indicate that the observed lymphoproliferation was probably the consequence of the chromosomal instability associated with the Artemis-deficient background. As a whole, our work provides a basis for supporting the gene therapy approach in Artemis-deficient SCID.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Lentivirus/genética , Proteínas Nucleares/genética , Imunodeficiência Combinada Severa/terapia , Animais , Linfócitos B/imunologia , Complexo CD3/análise , Antígenos CD4/análise , Antígenos CD8/análise , Células Cultivadas , Endonucleases , Feminino , Citometria de Fluxo , Terapia Genética/métodos , Vetores Genéticos/genética , Células-Tronco Hematopoéticas/citologia , Células-Tronco Hematopoéticas/metabolismo , Receptores de Hialuronatos/análise , Subunidade alfa de Receptor de Interleucina-2/análise , Masculino , Camundongos , Camundongos Knockout , Proteínas Nucleares/deficiência , Proteínas Nucleares/metabolismo , Imunodeficiência Combinada Severa/genética , Imunodeficiência Combinada Severa/imunologia , Linfócitos T/imunologia , Timo/imunologia , Timo/patologia , Transdução Genética
2.
Blood ; 108(4): 1123-8, 2006 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-16614244

RESUMO

Severe combined immunodeficiency (SCID) is characterized by a complete block in T-lymphocyte differentiation. Most SCID also affects B-cell development or function, although a normal pool of pro-B cells is detectable. Treatment of SCID consists of allogeneic hematopoietic stem cell transplantation (HSCT), but in the absence of a myeloablative conditioning regimen, only T cells, and in some cases, natural killer (NK) cells, are of donor origin, while all other leukocytes subsets are of host origin. We hypothesized that donor B-cell development success could be conditioned by the competitive ability of recipient B-cell precursors in the bone marrow. We therefore compared the outcome of unconditioned HSCT in mice that differed with respect to their pro-B-cell compartments. B-cell reconstitution was limited in recipient mice containing a normal pro-B-cell pool, whereas immature and mature B-cell numbers reached wild-type levels in mice with compromised early B-cell precursors. Interestingly, host NK cells did not modify the outcome of unconditioned HSCT as long as the early B-cell compartment was compromised. These observations suggest that recipient B-cell precursors condition the reconstitution of the donor B-cell pool and, if extrapolative to humans, suggest that conditioning regimens targeting host pro-B cells may help improve B-cell reconstitution after allogeneic HSCT.


Assuntos
Linfócitos B/imunologia , Diferenciação Celular/imunologia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/imunologia , Imunodeficiência Combinada Severa/imunologia , Quimeras de Transplante/imunologia , Animais , Humanos , Células Matadoras Naturais/imunologia , Camundongos , Imunodeficiência Combinada Severa/terapia , Linfócitos T/imunologia , Condicionamento Pré-Transplante , Transplante Homólogo
3.
Blood ; 107(1): 63-72, 2006 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-16174758

RESUMO

Severe combined immunodeficiency (SCID) caused by mutations in RAG1 or RAG2 genes is characterized by a complete block in T- and B-cell development. The only curative treatment is allogeneic hematopoietic stem cell transplantation, which gives a high survival rate (90%) when an HLA-genoidentical donor exists but unsatisfactory results when only partially compatible donors are available. We have thus been interested in the development of a potential alternative treatment by using retroviral gene transfer of a normal copy of RAG1 cDNA. We show here that this approach applied to RAG-1-deficient mice restores normal B- and T-cell function even in the presence of a reduced number of mature B cells. The reconstitution is stable over time, attesting to a selective advantage of transduced progenitors. Notably, a high transgene copy number was detected in all lymphoid organs, and this was associated with a risk of lymphoproliferation as observed in one mouse. Altogether, these results demonstrate that correction of RAG-1 deficiency can be achieved by gene therapy in immunodeficient mice but that human application would require the use of self-inactivated vector to decrease the risk of lymphoproliferative diseases.


Assuntos
Terapia Genética/métodos , Proteínas de Homeodomínio/administração & dosagem , Sistema Imunitário/efeitos dos fármacos , Regeneração/efeitos dos fármacos , Imunodeficiência Combinada Severa/terapia , Animais , Linfócitos B/citologia , Linfócitos B/imunologia , Dosagem de Genes , Terapia Genética/efeitos adversos , Proteínas de Homeodomínio/efeitos adversos , Proteínas de Homeodomínio/genética , Sistema Imunitário/fisiologia , Transtornos Linfoproliferativos/etiologia , Camundongos , Camundongos Knockout , Retroviridae/genética , Imunodeficiência Combinada Severa/complicações , Linfócitos T/citologia , Linfócitos T/imunologia
4.
Blood ; 100(12): 3942-9, 2002 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-12393742

RESUMO

Patients with mutations of either RAG-1 or RAG-2 genes suffer from severe combined immunodeficiency (SCID) characterized by the lack of T and B lymphocytes. The only curative treatment today consists of hematopoietic stem cell (HSC) transplantation, which is only partially successful in the absence of an HLA genoidentical donor, thus justifying research to find an alternative therapeutic approach. To this end, RAG-2-deficient mice were used to test whether retrovirally mediated ex vivo gene transfer into HSCs could provide long-term correction of the immunologic deficiency. Murine RAG-2-/-Sca-1(+) selected bone marrow cells were transduced with a modified Moloney leukemia virus (MLV)-based MND (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted) retroviral vector containing the RAG-2 cDNA and transplanted into RAG-2-/- sublethally irradiated mice (3Gy). Two months later, T- and B-cell development was achieved in all mice. Diverse repertoire of T cells as well as proliferative capacity in the presence of mitogens, allogeneic cells, and keyhole limpet hemocyanin (KLH) were shown. B-cell function as shown by serum Ig levels and antibody response to a challenge by KLH also developed. Lymphoid subsets and function were shown to be stable over a one-year period without evidence of any detectable toxicity. Noteworthy, a selective advantage for transduced lymphoid cells was evidenced by comparative provirus quantification in lymphoid and myeloid lineages. Altogether, this study demonstrates the efficiency of ex vivo RAG-2 gene transfer in HSCs to correct the immune deficiency of RAG-2-/- mice, constituting a significant step toward clinical application.


Assuntos
Proteínas de Ligação a DNA/administração & dosagem , Terapia Genética/métodos , Imunodeficiência Combinada Severa/terapia , Animais , Linfócitos B/citologia , Linfócitos B/imunologia , Células da Medula Óssea/metabolismo , Transplante de Medula Óssea , Divisão Celular , Linhagem da Célula , Proteínas de Ligação a DNA/genética , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Knockout , Receptores de Antígenos de Linfócitos T , Retroviridae/genética , Linfócitos T/citologia , Linfócitos T/imunologia , Transdução Genética , Integração Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...